Skip to main content
Premium Trial:

Request an Annual Quote

GeneFormatics Gotz Goes to ProSanos; Ex-Amgen Prez Hixson Joins Sequenom Board; and Others

NEW YORK, Jan. 15-ProSanos, a private California-based biomedical informatics company, hired Vincent Gotz as senior vice president for business solutions, the company said yesterday.


Gotz will direct business development, marketing, and account management.


Most recently, Gotz was chief business officer at GeneFormatics. He has also held management positions at Epicyte Pharmaceuticals, Dura Pharmaceuticals and Marion Merrell Dow.



Elitra Pharmaceuticals chairman and CEO Harry Hixson, Jr., joined Sequenom's board of directors, the company said on Jan. 14.


He will provide guidance for both the company's business units, Sequenom Genetic Systems and Sequenom Pharmaceuticals.


Hixson was president and chief operating officer of Amgen from 1988 to 1991, and has been involved in several biotechnology startups.



Lion Bioscience has shuffled its scientific advisory board and lost a chief scientific officer, the company said on Jan. 10.


H.C. Klaus Tschira, 62, who joined the board in 1999, has resigned to spend more time on his nonprofit Klaus Tschira Foundation.


Lion has recommended Richard Roy, the 47-year-old former chief of Microsoft Germany, as his replacement, and expects him to be confirmed at the next general shareholders' meeting. Roy would help the company's "redoubled focus on life science informatics," CEO Friedrich von Bohlen said in a statement.


Lion also said that Chief Scientific Officer Jan Mous has resigned following the December closing of the company's drug discovery business.


 Mous, who initially joined Lion from Hoffman-LaRoche in 2000, will continue to advise the company as a consultant.  



University of Massachusetts Medical School cell biologist and Howard Hughes Medical Institute researcher Craig Mello and Carnegie Institute of Washington scientific staff member Andrew Fire have won the National Academy of Sciences award in molecular biology, the academy said on Jan. 10.


The two won the medal and $250,000 prize for their work in RNAi gene inactivation.


NAS will formally present the award and 16 others in various scientific disciplines at a Washington, D.C. ceremony on April 28.



Cambridge Antibody Technology said that Peter Ringrose will become non-executive director to the board as of February 10, 2003.


Until his retirement in December 2002, Ringrose was chief scientific officer and president of Bristol-Myers Squibb Research Institute in Princeton, NJ. He also served as a member of the company's Executive Committee, responsible for global R&D.


Prior to his work at Bristol-Myers, Ringrose was senior vice president of worldwide drug discovery and European medicinal R&D at Pfizer, and has also worked at Sandoz Research Institute and Roche Research.



Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.